Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.

TypePublic
HQSan Francisco, US
Founded1990
Size (employees)468 (est)
Websitenektar.com
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Nektar Therapeutics

Robert Chess

Robert Chess

Chairman of the Board
Jillian Thomsen

Jillian Thomsen

Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth

Dorian Hirth

Senior Vice President, Human Resources and Facilities Operations
Timothy Riley

Timothy Riley

Senior Vice President, Technology Assessment and Quality Assurance
Show more

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Huntsville, US
1112 Church Street
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Show all (3)
Report incorrect company information

Nektar Therapeutics Financials and Metrics

Nektar Therapeutics Revenue

Embed Graph
Nektar Therapeutics's revenue was reported to be $307.71 m in FY, 2017
USD

Revenue (Q2, 2018)

1.1 b

Gross profit (Q2, 2018)

1.1 b

Gross profit margin (Q2, 2018), %

98.9%

Net income (Q2, 2018)

875.7 m

EBIT (Q2, 2018)

886.9 m

Market capitalization (14-Sep-2018)

10.2 b

Closing stock price (14-Sep-2018)

59.3

Cash (30-Jun-2018)

911.1 m
Nektar Therapeutics's current market capitalization is $10.2 b.
Annual
USDFY, 2013FY, 2014Y, 2015FY, 2016FY, 2017

Revenue

148.9 m200.7 m230.8 m165.4 m307.7 m

Revenue growth, %

35%15%(28%)

Cost of goods sold

38.5 m28.5 m34.1 m30.2 m30.5 m

Gross profit

110.4 m172.2 m196.7 m135.2 m277.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

60.9 m19.8 m28.5 m132.9 m108.8 m22.7 m60 m58.9 m32.8 m36.3 m24.7 m34.6 m38 m1.1 b

Cost of goods sold

12.9 m7.9 m5.1 m9.2 m8.4 m10.5 m6.8 m8.9 m7.7 m7 m6.1 m9 m6.6 m12.2 m

Gross profit

48 m11.9 m23.4 m123.7 m100.4 m12.1 m53.2 m50 m25.1 m29.3 m18.6 m25.6 m31.4 m1.1 b

Gross profit Margin, %

79%60%82%93%92%54%89%85%76%81%75%74%83%99%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

39.1 m12.4 m55.6 m59.6 m4.8 m

Accounts Receivable

Inventories

13.5 m13 m11.3 m11.1 m10.7 m

Current Assets

257.9 m288.2 m350.1 m426.3 m326.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

65.4 m32.4 m30.7 m32 m129.5 m20.9 m18.8 m72.5 m55.7 m63.3 m23.5 m16.1 m34.8 m911.1 m

Accounts Receivable

4.6 m1.9 m3 m46.1 m2.9 m3.7 m3 m39.7 m27.8 m14.2 m1.6 m4.1 m15.6 m35.3 m

Inventories

15.1 m12.9 m14.1 m11.7 m12.5 m10.1 m10.4 m11.3 m10.3 m10.8 m13 m11 m10.7 m11.9 m

Current Assets

207.9 m304.8 m298.2 m324.1 m347.3 m302.2 m286.4 m344.8 m318.3 m282.5 m381 m288.2 m336 m1.9 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(162 m)(53.9 m)(81.2 m)(153.5 m)(96.7 m)

Depreciation and Amortization

14.3 m12.9 m12.9 m15.4 m14.7 m

Inventories

4.8 m500 k1.6 m237 k383 k

Accounts Payable

6.2 m(6.4 m)(412 k)518 k2.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(16.5 m)(46.2 m)(32.6 m)70.6 m33.8 m(52.7 m)(8.2 m)(19.5 m)(48.6 m)(43.2 m)(63.9 m)(95.8 m)875.7 m

Depreciation and Amortization

3 m2.5 m5.1 m

Inventories

14.1 m11.7 m441 k10.1 m10.4 m11.3 m10.3 m10.8 m13 m51 k(1.2 m)

Accounts Payable

7.4 m5.4 m2.2 m2.8 m2.3 m2.3 m2.3 m7.1 m7 m6.5 m5.8 m
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Nektar Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Nektar Therapeutics News and Updates

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2018

SAN FRANCISCO, Aug. 8, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2018. Cash and investments in marketable securities at June 30, 2018 were $2.1 billion as compared to $353.2 million at December 31,...

Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA

SAN FRANCISCO, July 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment of chronic low back pain in adult...
Show more
Report incorrect company information

Nektar Therapeutics Company Life and Culture

Report incorrect company information